TCRX TScan Therapeutics, Inc.

NASDAQ
$0.15

TScan Therapeutics, Inc. (TCRX) is expected to report earnings on February 11, 2027, before the market open. The consensus earnings estimate is a loss of $0.16 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -18.9% since its last earnings release on November 12, 2026.

TScan Therapeutics, Inc. Missed Consensus Estimates
Thursday, November 12, 2026 · 7:00 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 11
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.16)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.16

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About TScan Therapeutics, Inc.

TScan is a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer.

Sector

Healthcare

Industry

Biotechnology

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.